Imagine a small-molecule compound that performs exceptionally well in early-stage biochemical assays, only to produce inconsistent or anomalous results when the study is repeated under slightly different conditions. Before questioning the compound itself, researchers often overlook a silent variable: the plastic consumables used throughout the workflow. Tubes, plates, and flasks are rarely scrutinized as potential sources of experimental error — yet the chemicals they release into samples can measurably alter biological and chemical outcomes. This article examines how plastic leachables introduce risk into drug discovery research and outlines practical strategies to manage that risk effectively.
Understanding Leachables and Extractables
Two terms are central to this discussion: extractables and leachables, and the distinction between them matters.
Extractables are chemical substances that migrate out of a plastic material under exaggerated laboratory conditions — elevated temperatures, aggressive solvents, or extended contact times. They represent a worst-case inventory of what a material could release and are typically identified through controlled stress testing.
Leachables are the subset of those substances that actually migrate into a sample under normal, intended-use conditions. These are the compounds of direct concern in everyday laboratory workflows.
Common leachable species from laboratory plastics include plasticizers such as phthalates (e.g., DEHP, DBP), antioxidant degradation products (e.g., compounds from the Irganox family), residual monomers, UV stabilizers, and mold-release agents. The identities and concentrations of these substances vary considerably depending on the polymer type, manufacturing process, and the additives used during production.
How Leachables Interfere with Drug Discovery
Compromising High-Throughput Screening Results
High-throughput screening (HTS) is foundational to early drug discovery, and it relies on the assumption that observed compound activity reflects true target engagement. Leachables can undermine this assumption in two ways: by directly interacting with the biological target, or by affecting assay reagents.
Certain phthalate-based plasticizers, for example, have documented estrogenic activity and can act as agonists or antagonists at nuclear receptors — precisely the class of targets frequently studied in HTS campaigns. A contaminant present at nanomolar concentrations in a 384-well plate could shift IC₅₀ values, generate false positives, or suppress genuine activity signals. These artifacts may not be identified until later stages, by which point substantial resources have been committed to pursuing a flawed lead.
Distorting Cell-Based Toxicity Assays
In cell-based assays, the cytotoxicity of leachables themselves can obscure or exaggerate the apparent toxicity of a drug candidate. If the plastic consumables used in a cell viability experiment introduce a basal level of cytotoxic contamination, the resulting data will systematically misrepresent the compound’s true safety profile. Early-stage toxicity assessments that are compromised in this way can lead to incorrect go/no-go decisions, either advancing unsafe compounds or terminating viable ones.
Destabilizing Biologic Drug Candidates
Protein-based therapeutics — monoclonal antibodies, fusion proteins, antibody-drug conjugates — are particularly sensitive to chemical contaminants. Leachables can induce protein aggregation, promote oxidative degradation of critical residues, and alter folding states in ways that affect both potency and immunogenicity assessment. For ADCs and other complex biologics, where the integrity of the molecular structure is essential to function, even trace-level contamination from storage tubes or sample processing plates represents a meaningful analytical risk.
Undermining Batch-to-Batch Reproducibility
Even when leachable levels are low enough to avoid overt interference, variability in leachable profiles between manufacturing lots of the same consumable can introduce unexplained inter-experiment variance. In regulated research environments governed by GLP principles, this kind of uncontrolled variable is a data integrity concern. When results cannot be reproduced and the source of variability cannot be attributed, the reliability of the entire dataset is called into question.
High-Risk Steps in a Typical Drug Discovery Workflow
Not all laboratory steps carry equal leachable risk. The following scenarios represent points of elevated exposure:
- Compound storage and management: Long-term storage in polypropylene tubes allows cumulative leachable migration, particularly when compounds are dissolved in DMSO or aqueous buffers.
- High-throughput screening: Microplates (96- and 384-well formats) present a high surface-area-to-volume ratio, increasing the relative contribution of any leached material to the sample volume.
- Cell culture: Culture flasks and dishes are in prolonged contact with growth media, creating conditions favorable to sustained leachable migration.
- Protein sample processing: Centrifuge tubes and pipette tips used in protein workflows introduce both leachable and adsorption risks simultaneously.
- Cryogenic storage: Low-temperature behavior of plastics differs from ambient behavior; leachable profiles at −80°C may not reflect room-temperature test data.
Strategies for Mitigating Leachable Risk
Prioritize Material Selection
Polymer choice is the most fundamental control. Polypropylene (PP) generally offers a favorable profile for laboratory use, as it requires fewer additives than polyethylene and avoids the residual monomer concerns associated with polystyrene. Across all polymer types, consumables manufactured from virgin-grade resins — materials that have not been recycled or reprocessed — present a more predictable and typically lower leachable burden than those made from blended or recovered feedstocks.
Apply Relevant Quality and Regulatory Standards
When evaluating consumables for drug discovery applications, two quality standards carry particular relevance:
USP Class VI biological reactivity testing provides a standardized assessment of plastic material safety under physiological conditions and is widely referenced in pharmaceutical research contexts.
ISO 13485 certification — the international standard for quality management systems in medical device manufacturing — is a meaningful indicator that a supplier maintains rigorous, auditable controls over raw material sourcing, production consistency, and product traceability. For researchers sourcing consumables intended for use in regulated or semi-regulated drug discovery workflows, ISO 13485-certified suppliers offer a higher degree of supply chain assurance than those operating under general manufacturing standards alone.
Suppliers should also be able to provide Certificates of Conformance (CoC) and, where applicable, extractables/leachables test data for their product lots.
Control Operational Variables
Beyond material selection, procedural discipline reduces leachable exposure. Avoid prolonged contact between plastic consumables and solvents outside their validated compatibility range. Implement blank control experiments as a routine practice to monitor background contamination levels. Establish clear storage time limits for sample-containing plasticware, and document lot numbers to support traceability in the event of anomalous results.
Evaluate Supplier Consistency
Lot-to-lot consistency is a critical but often underweighted criterion in consumable procurement. Suppliers of life science-grade plastic consumables should be able to demonstrate that their leachable profiles remain stable across production batches — not merely that a single lot passed a qualification test. Requesting multi-lot extractables data, where available, provides a more accurate basis for risk assessment than single-point certification.
Conclusion
Plastic leachables represent a low-visibility but consequential source of experimental variability in drug discovery research. Their effects span the full breadth of the discovery workflow — from compound screening and cell-based assays to biologic characterization and long-term sample storage. Addressing this risk does not require wholesale changes to laboratory practice; it requires informed material selection, an understanding of where in the workflow exposure is greatest, and a disciplined approach to supplier qualification. In a field where data quality directly determines the efficiency of the development pipeline, the consumables used to generate that data deserve the same level of scrutiny as any other experimental variable.
